Skip to main content
. 2013 May 20;14(1):55. doi: 10.1186/1465-9921-14-55

Table 2.

Effect estimates of listed parameters on baseline % lung volume <-950 HU values

Parameter Effect size p-value. 95% CI of effect size
Lower bound Upper bound
Center
 
 
 
 
UMCU
0.87
<0.001
0.83
0.91
UMCG (reference)
 
 
 
 
smoking group
 
 
 
 
current smoker
0.60
<0.001
0.56
0.64
quitted <1 year
0.90
0.033
0.81
0.99
quitted ≥1 – <5 years
0.99
0.956
0.93
0.99
quitted ≥5years (reference)
 
 
 
 
baseline GOLD stage
 
 
 
 
normal
0.17
0.013
0.04
0.68
stage I
0.26
0.065
0.06
1.08
stage II
0.29
0.089
0.07
1.21
stage III
0.46
0.279
0.11
1.89
stage IV (reference)
 
 
 
 
Presence of respiratory symptoms
 
 
 
 
cough
0.87
0.980
0.82
0.91
wheezing
0.97
0.449
0.90
1.05
dyspnea
1.00
0.786
0.94
1.08
mucus
1.02
0.568
0.95
1.09
height (cm)
1.01
<0.001
1.01
1.02
age at start study (years)
1.02
<0.001
1.01
1.02
packyears 0.99 <0.001 0.99 1.00

The column headed with ‘effect size’ gives the change in % lung volume <-950 HU due to a unit change in the parameter or due to membership of another class. So for each year a subject is older at the start of the study, the % lung volume <-950 HU increases with a factor or1.02 per year. For class comparisons the changes are versus the reference group: so a subject with an FEV1/FVC >70% (no COPD) has 0.17 times lower % lung volume <-950 HU compared to the reference GOLD class 4 (the p-value for this comparison is <0.001).